Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

27 Sep 2005 12:09

Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2005 Chairman's statementIn the six months ended 30 June 2005 the Company incurred a loss before andafter taxation of ‚£74,000 (2004: ‚£229,000).Because of the lack of cash in the Company, creditors have increased butcontinue to be supportive.The directors are continuing to keep overheads to a minimum, the expenses beingthose necessary to maintain the Company's listing on AIM.The board continues to seek an acquisition for the Company.Owing to a technicality, the Company no longer has any authority to issue anyof its share capital and will therefore be convening an extraordinary generalmeeting for this purpose.Nicolas GreenstoneChairman27 September 2005Azure Holdings plcProfit and Loss Accountfor the six months ended 30 June 2005 6 months 6 months Year ended ended 30 ended 30 31 December June 2004 2004 June 2005 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000 Turnover - - - Administrative expenses (74) (229) (345) Operating loss (74) (229) (345) Loss on ordinary activities before (74) (229) (345)taxation Tax on loss on ordinary activities - - - Loss on ordinary activities after (74) (229) (345)taxation Retained loss for the period (74) (229) (345) Loss per ordinary share (0.15p) (0.65p) (0.86p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains andlosses.Azure Holdings plcBalance Sheetas at 30 June 2005 30 June 2005 30 June 31 December 2004 2004 (unaudited) (unaudited) (audited) ‚£'000 ‚£'000 ‚£'000 Current assets Debtors 3 14 7 Cash at bank and in hand 1 10 14 4 24 21 Creditors: amounts falling due within one (147) (81) (90)year Net current liabilities (143) (57) (69) Total assets less current liabilities (143) (57) (69) Net liabilities (143) (57) (69) Capital and reserves Called up Share Capital 5,475 5,371 5,475 Share Premium 10,279 10,279 10,279 Profit and loss account (15,897) (15,707) (15,823) Equity shareholders deficit (143) (57) (69) Azure Holdings plcCash Flow Statementfor the six months ended 30 June 2005 6 months ended 6 months ended 30 June 2005 30 June 2004 (unaudited) (unaudited) ‚£'000 ‚£'000 Net cash outflow from operating (13) (214)activities Financing Issue of ordinary shares - 105 Decrease in cash (13) (109)Azure Holdings plcNotes to the Interim Results 1. The interim results are unaudited and do not constitute statutory accounts within the meaning of section 240 of the Companies Act 1985. The figures for the year ended 31 December 2004 have been extracted from the statutory accounts filed with the registrar of companies on which the auditors gave an unqualified report. 2. The interim results have been prepared using the accounting policies set out in the statutory accounts for the year ended 31 December 2004. 3. The comparative figures for the unaudited interim results for the period ended 30 June 2004 are stated as announced on 29 September 2004. 4. Loss per share The earnings per share for the six months ended 30 June 2005 has beencalculated on the basis of the loss after taxation for the period of ‚£74,000(2004: ‚£229,000 ) and the weighted average number of shares in issue during theperiod of 48,317,569 (2004: 35,417,565). 5. The directors do not propose to pay a dividend for the period. 6. Copies of the interim results are available from the Company's registered office, One Great Cumberland Place, London, W1H 7AL. ENDAZURE HOLDINGS PLC
Date   Source Headline
14th Jul 202210:46 amRNSHolding(s) in Company
13th Jul 20222:15 pmRNSSuccessful evaluation of breast cancer programme
7th Jul 202211:07 amRNSDirector/PDMR Shareholding
5th Jul 202211:45 amRNSHolding(s) in Company
5th Jul 20227:00 amRNSBroker Option Results
30th Jun 20223:00 pmRNSResult of AGM and Appointment of Joint Broker
30th Jun 202210:31 amRNSIssue of Equity
30th Jun 202210:30 amRNSExtends exclusivity period for TheoremRx
17th Jun 202210:01 amRNSUpdate on VAL201 sub-license agreement
7th Jun 20224:33 pmRNSAnnual Report, AGM Notice & Director Resignation
23rd Mar 20227:00 amRNSUpdate on proposed sub-license of VAL201
15th Mar 20227:00 amRNSOperational and Strategy Update
14th Feb 20227:00 amRNSEvaluation agreement with University of Barcelona
5th Jan 20224:41 pmRNSSecond Price Monitoring Extn
5th Jan 20224:36 pmRNSPrice Monitoring Extension
5th Jan 20222:06 pmRNSSecond Price Monitoring Extn
5th Jan 20222:00 pmRNSPrice Monitoring Extension
5th Jan 202211:00 amRNSPrice Monitoring Extension
5th Jan 20229:06 amRNSSecond Price Monitoring Extn
5th Jan 20229:00 amRNSPrice Monitoring Extension
5th Jan 20227:16 amRNSSigns Service Agreement with TheoremRx
20th Dec 20217:00 amRNSAmends License for VAL201 with CRT
16th Dec 202110:46 amRNSEvaluation agreement with Hokkaido University
11th Nov 20217:00 amRNSLive Shareholder Q&A and Investor presentations
8th Nov 20213:03 pmRNSHolding(s) in Company
2nd Nov 20217:00 amRNSSigns Letter of Intent to Sub-License VAL201
26th Oct 20212:00 pmRNSPrice Monitoring Extension
26th Oct 202111:05 amRNSSecond Price Monitoring Extn
26th Oct 202111:00 amRNSPrice Monitoring Extension
26th Oct 20217:00 amRNSHolding(s) in Company
20th Oct 20211:19 pmRNSHolding(s) in Company
19th Oct 202112:23 pmRNSHolding(s) in Company
18th Oct 20214:41 pmRNSSecond Price Monitoring Extn
18th Oct 20214:36 pmRNSPrice Monitoring Extension
18th Oct 20212:06 pmRNSSecond Price Monitoring Extn
18th Oct 20212:01 pmRNSPrice Monitoring Extension
18th Oct 202111:06 amRNSSecond Price Monitoring Extn
18th Oct 202111:00 amRNSPrice Monitoring Extension
30th Sep 20212:45 pmRNSHolding(s) in Company
30th Sep 202112:24 pmRNSHolding(s) in Company
28th Sep 20214:41 pmRNSSecond Price Monitoring Extn
28th Sep 20214:36 pmRNSPrice Monitoring Extension
17th Sep 20214:41 pmRNSSecond Price Monitoring Extn
17th Sep 20214:36 pmRNSPrice Monitoring Extension
16th Sep 20217:00 amRNSNew Evaluation Agreement
8th Sep 20217:00 amRNSHolding(s) in Company
7th Sep 20217:00 amRNSHalf-year Report
25th Aug 20217:00 amRNSAppointment of Broker
20th Aug 20212:05 pmRNSSecond Price Monitoring Extn
20th Aug 20212:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.